Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04121728
Other study ID # 2018-02134 BASEC
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 9, 2019
Est. completion date May 31, 2024

Study information

Verified date January 2023
Source University of Lausanne Hospitals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to simultaneously establish the metrological characteristics of the new executive function markers (decision making and multiple flow management) derived from repeated ERP variations and to identify their ability to test whether a short treatment using Ginkgo biloba versus placebo extracts can modify the cognitive performance and functional capacity of patients in the very early stages of age-related cognitive decline. This trial, using subjects as their own control (cross-over) in repeated measurements will establish the reproducibility characteristics of the measurements and intra-individual variations of ERP over time in this population


Description:

This study is a single-center, randomized clinical trial testing the effects of Ginkgo biloba extracts versus placebo on event related potential ERP registration measurements in Electroencephalography (EEG) during neuropsychological tasks. The Hold-Release (HR) neuropsychological test allows the study of behavioral and neurofunctional correlates using several different techniques for online recording of brain activity. This test measures the engagement of focused attention and the loading of information into working memory, as opposed to the disengagement of attention. The study will be carried out in a randomized cross-over design, with "Ginkgo" vs. Placebo", or inversely, for 170 days each (approximately 6 months), separated by an 8-weeks wash-out period. A follow-up visit will be held 3 months after the last treatment of the study. The cross-over design uses each patient as its own control, which allows an easy comparison between the 2 groups "Placebo" vs. "Ginkgo" by limiting inter-patient variations. In addition, by doubling the number of patients per treatment compared to a classic study design in 2 groups, cross-over reduces the number of patients to be recruited, which facilitates recruitment on a single site. The study requires the recruitment of sixteen (16) informative participants with cognitive complaints.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 16
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 80 Years
Eligibility Inclusion Criteria - Signed consent form - men and women - 60 to 80 years old - Diagnostic of Subjective complain - Understanding the 2 Hold-Release tasks in ERP Exclusion Criteria: - Montreal Cognitive Evaluation Score (MoCA) <24 - Overall Clinical Dementia Rating (CDR) score > 0.5 - Scores of the Hospital Anxiety and Depression Scale (HADS): HADS-A (Anxiety) > 8 and/or HADS-D (Depression) > 8 - Mild Cognitive Impairment (MCI) or dementia - Contraindication to MRI - Atrophy of any region of the brain as seen in the T1 volumetric MRI sequence - Any uncontrolled somatic or psychiatric condition - Bleeding disorders, and/or taking medications that increase the risk of bleeding, - Hypersensitivity to Ginkgo biloba or any of its excipients - Lactose intolerance - Treatment with barbiturates and/or neuroleptics - Ongoing treatment with Ginkgo biloba derivatives (a period of 2 months without treatment before inclusion is required

Study Design


Intervention

Drug:
Ginkgo biloba extract
Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
Placebo
The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.

Locations

Country Name City State
Switzerland Centre Leenaards de la mémoire (CLM) CHUV Lausanne Vaud

Sponsors (2)

Lead Sponsor Collaborator
Jean-François Démonet University of Lausanne Hospitals

Country where clinical trial is conducted

Switzerland, 

References & Publications (6)

Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008 Nov;64(5):492-8. doi: 10.1002/ana.21509. — View Citation

Kennedy DO, Scholey AB, Drewery L, Marsh VR, Moore B, Ashton H. Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. Pharmacol Biochem Behav. 2003 Jun;75(3):701-9. doi: 10.1016/s0091-3057(03)00120-5. — View Citation

Luck T, Luppa M, Matschinger H, Jessen F, Angermeyer MC, Riedel-Heller SG. Incident subjective memory complaints and the risk of subsequent dementia. Acta Psychiatr Scand. 2015 Apr;131(4):290-6. doi: 10.1111/acps.12328. Epub 2014 Sep 9. — View Citation

Martin CD, Thierry G, Demonet JF. ERP characterization of sustained attention effects in visual lexical categorization. PLoS One. 2010 Mar 25;5(3):e9892. doi: 10.1371/journal.pone.0009892. — View Citation

Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2015;43(2):589-603. doi: 10.3233/JAD-140837. — View Citation

Thierry G, Doyon B, Demonet JF. ERP mapping in phonological and lexical semantic monitoring tasks: A study complementing previous PET results. Neuroimage. 1998 Nov;8(4):391-408. doi: 10.1006/nimg.1998.0371. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Predictive metrological characteristics of ERP modulation in term of its ability to detect a more sensitive cognitive variation than usual method a mixed linear model approach will be applied to assess prediction through study completion, an average of 14 months
Other Predictive metrological characteristics of ERP modulation in term of its ability to detect a slope break during cognitive decline a mixed linear model approach will be applied to assess prediction through study completion, an average of 14 months
Primary Reproducibility of contingent negative variation (CNV) event-related potential (ERP) component amplitude (microV) during the Hold-Release (HR) neuropsychological test Reproducibility of CNV will be assessed by interclass correlation coefficient (ICC) through study completion, an average of 14 months
Primary Intra-individual variability of contingent negative variation (CNV) event-related potential (ERP) component amplitude (microV) during the Hold-Release (HR) neuropsychological test Intra-individual variability of CNV will be assessed by Interclass Coefficient Correlation (ICC) through study completion, an average of 14 months
Primary Reproducibility of P300/P300' event-related potential (ERP) component amplitude (microV) during the Hold-Release (HR) neuropsychological test Reproducibility of P300/P300' will be assessed by Interclass Coefficient Correlation (ICC) through study completion, an average of 14 months
Primary Intra-individual variability of P300/P300' event-related potential (ERP) component amplitude (microV) during the Hold-Release (HR) neuropsychological test Intra-individual variability of P300/P300' will be assessed by Interclass Coefficient Correlation (ICC) through study completion, an average of 14 months
Primary Change in cognitive performance as assessed by variation in amplitude (mivroV) of the CNV component measured during the Hold-Release (HR) neuropsychological test after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used through study completion, an average of 14 months
Primary Change in cognitive performance as assessed by variation in amplitude (mivroV) of the P300/P300' component measured during the Hold-Release (HR) neuropsychological test after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used through study completion, an average of 14 months
Secondary Change in cognitive performance as assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) test after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used 6 months
Secondary Change in scores of categorical semantic verbal fluency after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used 6 months
Secondary Change in scores of verbal fluency letter instruction after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used 6 months
Secondary Change in anxiety and depression as assessed using the Hospital Anxiety and Depression Scale (HAD-A/D) after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used 6 months
Secondary Change in reaction time (ms) during the Hold-Release (HR) neuropsychological test after 6 months of Ginkgo biloba treatment the statistical model of repeated measurements of variance analysis will be used 6 months
Secondary Magnitude of repetition effects (Test-retest Reliability, TTR) on the contingent negative variation (CNV) event-related potential (ERP) component during the Hold-Release (HR) neuropsychological test. Combination of an analysis of variance (ANOVA) in repeated measurements and an analysis of variance (ANOVA) in correlation analysis will be used to assess respectively differences (microV) between measurement sessions and the existence of shared associations (correlation coefficient). through study completion, an average of 14 months
Secondary Magnitude of repetition effects (Test-retest Reliability, TTR) on P300/P300' event-related potential (ERP) component during the Hold-Release (HR) neuropsychological test. Combination of an analysis of variance (ANOVA) in repeated measurements and an analysis of variance (ANOVA) in correlation analysis will be used to assess respectively differences (microV) between measurement sessions and the existence of shared associations (correlation coefficient). through study completion, an average of 14 months
Secondary Association (correlation coefficient) between a transversal measurement of VPN event-related potential (ERP) component during the Hold-Release (HR) neuropsychological test and the conventional verbal fluency scores. a mixed linear model approach will be applied to assess prediction through study completion, an average of 14 months
Secondary Association (correlation coefficient) between a transversal measurement of P300/P300' event-related potential (ERP) component during the Hold-Release (HR) neuropsychological test and the conventional verbal fluency scores. a mixed linear model approach will be applied to assess prediction through study completion, an average of 14 months
Secondary Association (correlation coefficient) between a transversal measurement of VPN event-related potential (ERP) component during the Hold-Release (HR) neuropsychological test and evolution of its own value during the participant's follow-up a mixed linear model approach will be applied to assess prediction through study completion, an average of 14 months
Secondary Association (correlation coefficient) between a transversal measurement of P300/P300' event-related potential (ERP) component during the Hold-Release (HR) neuropsychological test and evolution of its own value during the participant's follow-up a mixed linear model approach will be applied to assess prediction through study completion, an average of 14 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03516734 - Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh N/A
Not yet recruiting NCT05428228 - Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults N/A
Completed NCT05073406 - Cognition at Altitude in HEMS - Part II N/A
Completed NCT05498129 - School Feeding to Improve Cognitive Performance in Disadvantaged Children N/A
Completed NCT05226039 - The Effects of a Single Bout of Aerobic Exercise on Cognition: The Moderating Role of Age N/A
Completed NCT03169283 - Investigation of How Morning Nutrition Influences Cognitive Performance N/A
Completed NCT01794351 - Cognitive Effects of 500mg Trans-resveratrol N/A
Completed NCT02051153 - Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls N/A
Completed NCT00607204 - Examining the Biological Factors That Affect Sleep Duration N/A
Terminated NCT04056650 - Assessing the Effectiveness of an N-of-1 Platform Using Study of Cognitive Enhancers Phase 4
Recruiting NCT05481424 - Evaluating the Potentials of Biodynamic Lighting for Home Office Workers N/A
Completed NCT05281146 - Production of Fortified Biscuit With Chickpea and Crushed Peanut for Improving Cognitive Performance N/A
Completed NCT00395668 - TETRA (Terrestrial Trunked Radio) Phase 4
Active, not recruiting NCT03771716 - Rhythm Experience and Africana Culture Trial N/A
Active, not recruiting NCT03567343 - Investigational Test of a New Sleep Supplement N/A
Completed NCT05032729 - Nutritional Intervention to Enhance Sleep Quality and Quantity in Athletes N/A
Completed NCT04676542 - The Effects of Externally Paced Exercise on Cognitive Performance and Stress in College Aged Students N/A
Not yet recruiting NCT05904431 - The Effect of Cognitive Performance on Physical Performance in Adolescent Basketball Players
Completed NCT04974606 - Effect of Coffeeberry on Mood, Motivation and Cognitive Performance N/A
Recruiting NCT05598047 - Executive Functioning Training Study Phase 2